Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy

Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy

Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...

Full description

Saved in:
Bibliographic Details
Main Authors: Shota Kaburaki, Naoko Okada, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Yasuhiro Terasaki, Kazuo Kasahara, Masahiro Seike
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Transbronchial lung cryobiopsy
drug-induced interstitial lung disease
ixekizumab
psoriasis
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items